BridgeBio Pharma, Inc. (BBIO)

Current Report Filed: 2026-05-13

Key Insights

BridgeBio has submitted a New Drug Application (NDA) to the FDA for Encaleret, a treatment for Autosomal Dominant Hypocalcemia Type 1 (ADH1), representing a significant regulatory milestone that could lead to the company's first commercial product approval.
This NDA submission demonstrates progress in BridgeBio's clinical pipeline and validates their therapeutic approach, though FDA approval is not guaranteed and the review timeline remains uncertain.
The filing was signed by Thomas Trimarchi (President and CFO), indicating senior management's direct involvement in material developments, though the 8-K itself contains minimal financial or strategic details beyond the press release announcement.

Insider Trading Filed: 2026-05-11

Key Insights

CEO Kumar Neil executed a systematic sale of approximately 59,000 shares of BBIO common stock directly held between May 7-8, 2026, at prices ranging from $66.10 to $69.18 per share, generating roughly $4 million in proceeds through a pre-established Rule 10b5-1 trading plan adopted on March 31, 2025.
The filing reveals significant indirect holdings through two trusts (Kumar Haldea Family Irrevocable Trust and Kumar Haldea Revocable Trust) totaling approximately 8.9 million shares, with concurrent sales reducing trust holdings from ~600,000 to ~555,000 shares in the family irrevocable trust and ~4.4 million to ~4.35 million in the revocable trust.
The use of a pre-planned Rule 10b5-1 trading plan indicates the CEO's sales were pre-arranged and not based on material non-public information, which reduces concerns about negative signaling; however, the systematic liquidation pattern over two trading days suggests deliberate portfolio rebalancing or diversification rather than opportunistic selling.

Current Report Filed: 2026-05-08

Key Insights

BridgeBio established a $500 million at-the-market (ATM) offering program with Goldman Sachs and Leerink Partners, providing flexible capital raising capability without immediate dilution, suggesting the company is preparing for potential liquidity needs or strategic investments.
The company terminated its previous equity distribution agreement from May 2023 and replaced it with a new one, indicating a strategic refresh of financing arrangements after approximately 3 years, potentially reflecting improved market conditions or evolving capital strategy.
With a 3.0% commission structure on gross proceeds, the ATM offering provides cost-efficient capital access compared to traditional equity financing methods, allowing the company to raise funds opportunistically based on market conditions and operational needs.

Insider Trading Filed: 2026-04-13

Key Insights

Insider Neil Kumar sold a total of 59,000 shares of BridgeBio Pharma, Inc. (BBIO) stock on April 9-10, 2026, indicating some insider selling activity.
Kumar's sales were made pursuant to a Rule 10b5-1 sales plan, suggesting the transactions were pre-planned rather than opportunistic.
Kumar continues to hold a significant indirect beneficial ownership position of over 4.4 million shares through trusts, suggesting he retains a large stake in the company.

Current Report Filed: 2026-03-30

Key Insights

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for its product candidate BBP-418 to treat individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare genetic disorder.
The submission of the NDA represents a significant milestone for the company as it moves towards potential regulatory approval and commercialization of BBP-418 for this patient population with limited treatment options.
The successful NDA submission signals BridgeBio's progress in its pipeline development and its commitment to addressing unmet medical needs in rare genetic diseases.

Insider Trading Filed: 2026-03-20

Key Insights

The reporting person, Thomas Trimarchi, acquired 59,041 shares of BridgeBio Pharma, Inc. (BBIO) common stock through a grant of restricted stock units (RSUs) under the company's equity incentive plan. This indicates insider ownership and alignment with shareholder interests.
The RSUs have a vesting schedule of 1/16th per quarter, suggesting a long-term incentive structure for the reporting person to remain with the company.
The reporting person's total beneficial ownership of BBIO common stock increased to 395,626 shares, representing a significant equity stake in the company.

Insider Trading Filed: 2026-03-20

Key Insights

The reporting person, Maricel Apuli, received a grant of 14,170 restricted stock units (RSUs) under the company's equity incentive plan, which will vest over time as she continues her service as Chief Accounting Officer.
The grant of RSUs represents an equity-based compensation award that aligns Apuli's interests with those of shareholders, as the value of her award will rise and fall with the company's stock price.
Insider transactions like this can provide insight into management's confidence in the company's future prospects, though the significance of a single RSU grant may be relatively modest.

Insider Trading Filed: 2026-03-19

Key Insights

Neil Kumar, the CEO of BridgeBio Pharma, has acquired 40,570 stock options and 104,313 restricted stock units, indicating his confidence in the company's future prospects.
The vesting schedule for the stock options and RSUs is structured to incentivize Kumar's long-term commitment, with 1/16th of the shares vesting quarterly over the next 4 years.
This insider transaction suggests that the CEO believes BridgeBio Pharma is well-positioned for growth, as he is increasing his personal stake in the company.

Insider Trading Filed: 2026-03-12

Key Insights

The reporting person, Hannah Valantine, exercised 8,671 stock options and immediately sold the same amount of shares, suggesting a desire to generate some liquidity.
The reported transaction was made pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned and systematic approach to the insider's trading activity.
The reporting person still holds a significant direct ownership stake of 16,136 shares, as well as an indirect stake of 398 shares held by their spouse, suggesting ongoing commitment to the company.

Insider Trading Filed: 2026-03-06

Key Insights

The reporting person, Andrea Ellis, is a director of BridgeBio Pharma, Inc. and has exercised 64,921 stock options and sold the same number of shares, potentially indicating a transaction under a pre-arranged 10b5-1 trading plan.
The reported transaction price of $64.8681 per share is higher than the exercise price of $8.45 per share, suggesting the director may have realized a significant gain from the transaction.
The remaining 18,589 shares still held by the director represent a relatively small ownership position, which could indicate that the director is diversifying their holdings or taking some cash off the table.

Annual Report Filed: 2026-02-24

Key Insights

BridgeBio Pharma's revenue is projected to grow significantly in 2025, driven by increased sales of its product candidates and licensing/service agreements.
The company has a high degree of customer concentration risk, with a few key customers accounting for a significant portion of its revenue and accounts receivable.
BridgeBio Pharma has taken on significant debt financing through convertible senior notes and a term loan, which may impact its financial flexibility going forward.

Current Report Filed: 2026-02-24

Key Insights

BridgeBio Pharma reported its Q4 2025 and full-year 2025 financial results, providing an update on its recent business activities.
The company did not provide any financial guidance or updates on its key pipeline programs, which could be a concern for investors.
The absence of material news or catalysts in this 8-K filing suggests it may be a routine quarterly update without significant developments.

Insider Trading Filed: 2026-02-23

Key Insights

Insider Neil Kumar, the CEO, has sold a significant number of shares in BridgeBio Pharma, Inc. (BBIO) totaling over 27,000 shares in a single day.
The sales were executed pursuant to a pre-planned 10b5-1 trading plan, suggesting the transactions were not opportunistic.
Kumar retains a large indirect beneficial ownership of over 5 million shares in the company, indicating he remains heavily invested in BridgeBio's long-term success.

Insider Trading Filed: 2026-02-12

Key Insights

Neil Kumar, CEO of BridgeBio Pharma, has been actively selling shares in the company, disposing of over 46,000 shares in recent transactions.
Kumar's sales have been made pursuant to a pre-established 10b5-1 trading plan, suggesting the transactions may be part of a planned strategy rather than in response to new information.
The sales represent a relatively small portion of Kumar's overall holdings, as he continues to beneficially own over 4.5 million shares through various trusts for which he is a co-trustee.

Current Report Filed: 2026-02-12

Key Insights

BridgeBio Pharma reported positive Phase 3 topline results for its oral infigratinib treatment, which achieved statistically significant improvements in body proportionality for patients with achondroplasia.
The successful Phase 3 trial represents a major milestone for BridgeBio's pipeline and could potentially lead to regulatory approval and commercialization of this new therapy.
Investors may view this as a positive development for the company, as it demonstrates BridgeBio's ability to advance its drug candidates through late-stage clinical trials and achieve meaningful clinical outcomes.

Current Report Filed: 2026-01-21

Key Insights

BridgeBio Pharma issued $632.5 million in 0.75% Convertible Senior Notes due 2033, with the net proceeds used to repay existing convertible notes and for general corporate purposes.
The new convertible notes are convertible into cash, shares of BridgeBio's common stock, or a combination, at BridgeBio's election, with an initial conversion price of $110.58 per share.
BridgeBio also intends to use $82.5 million of cash to repurchase 1,081,825 shares of its common stock from certain purchasers of the notes in privately negotiated transactions.

Current Report Filed: 2026-01-12

Key Insights

BridgeBio Pharma reported preliminary Q4 2025 and full-year 2025 financial results, indicating strong net product revenue growth and a healthy cash position to support ongoing operations.
The company is making progress with its clinical development pipeline, including the new antibody depleter program for ATTR-CM and expected regulatory filings for BBP-418 and encaleret.
BridgeBio continues to execute on its strategy of rapidly advancing its diverse portfolio of rare disease therapies, positioning the company for potential future value creation.

Insider Trading Filed: 2026-01-12

Key Insights

Insider Neil Kumar has sold a significant amount of BridgeBio Pharma's (BBIO) common stock, totaling over 1.2 million shares across multiple transactions on January 8-9, 2026.
The sale transactions were executed pursuant to a pre-arranged 10b5-1 trading plan, indicating the sales were likely part of a planned strategy rather than a reactive move.
The sales represent a substantial reduction in Kumar's beneficial ownership, from over 4.5 million shares to under 1 million shares, suggesting he may be seeking to diversify his personal portfolio.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information